Kerrisdale Capital Management is an investment management company that was founded by Sahm Adrangi who also serves as the Chief Investment Officer. The firm focuses on mostly event driven special situations and long term value investments. Kerrisdale Capital has a short position at a company they previously gave a negative report, Proteostasis Therapeutics. This is a clinical stage biopharmaceutical company that discovers and develops therapeutics to treat among other diseases, cystic fibrosis. One such novel therapeutic is their lead product, PTI-428.
In claims refuted by Sahm Adrangi’s Kerrisdale Capital, Proteostasis claims that PTI-428 works uniquely by increasing levels of messenger RNA and protein correspondence to the gene CFTR. They supposedly performed a clinical trial that showed the drug meaningfully improved lung function as compared to placebo. In response, Sahm Adrangi and Kerrisdale Capital argued that these results were not wholly true. This is because the patients who received PTI-428 did not necessarily react extremely good to it, but rather the patients on placebo reacted poorly. On the other hand, CFTR mRNA and protein are very scarce in even the airway epithelium, further proving the drug is not as effective as Proteostasis claim because it would not be easy to measure favored biomarkers.
Sahm Adrangi has been with Kerrisdale Capital Management since founding it in 2009. Kerrisdale Capital Management is based in New York and makes value-oriented investments in public securities. He had previously held various positions in other companies. Among them, he was an Investment Analyst at Longacre Fund Management, LLC, Analyst at Chanin Capital Partners and Analyst at Deutsche Bank. Sahm Adrangi is a graduate of Yale University, where he received a Bachelor of Arts in Economics in 2003. He is widely known for exposing fraudulent companies and action against these companies taken by the Securities and Exchange Commission. Under Sahm Adrangi, Kerrisdale has published reports on specific sectors it acquaints with like mining, telecommunications and biotechnology. He is also a known activist, speaker and has as well appeared in interviews at Bloomberg and CNBC.